Coronary Artery Disease Without Standard Cardiovascular Risk Factors

Ko Yamamoto(Kyoto University), Takeshi Kimura(Municipal Hirakata City Hospital), Takeshi Aoyama(Hyogo Medical University), Hidenori Yaku(Kyoto University), Yasuaki Takeji(Kanazawa University), Masayuki Fuki(Tenri Hospital), Yukihito Sato(Hyogo Prefectural Amagasaki General Medical Center), Hiroki Watanabe(Kyoto University), Yugo Yamashita(Kyoto University Hospital), Manabu Shirotani(Hyogo Medical University), Eiji Shinoda(Hyogo Medical University), Yutaka Furukawa(Kobe City Medical Center General Hospital), Kenji Andò(Kokura Memorial Hospital), Yukiko Matsumura‐Nakano(Kyoto University), Erika Yamamoto(Kyoto University), Yusuke Yoshikawa(Kyoto University), Hiroki Shiomi(Kyoto University), Satoru Suwa(Juntendo University Shizuoka Hospital), Moriaki Inoko(Hyogo Medical University), Tomoya Onodera(Shizuoka City Hospital), Katsuhisa Ishii(Hyogo Medical University), Kenji Nakatsuma(Kyoto University), Kazushige Kadota(Kurashiki Central Hospital), Takashi Yamamoto(Koga Hospital), Yoshihisa Nakagawa(Shiga University of Medical Science), Takeshi Morimoto(Hyogo Medical University), Tsukasa Inada(Osaka Red Cross Hospital), Mamoru Toyofuku(Japanese Red Cross Society Wakayama Medical Center), Hiroshi Eizawa(Hyogo Medical University), Toshihiro Tamura(Tenri Hospital), Masahiro Natsuaki(Saga University), Hiroshi Mabuchi(Koto Hospital), Shinji Miki(Hyogo Medical University), Mamoru Takahashi(Hyogo Medical University), Mitsuo Matsuda(Kishiwada City Hospital), Eri Kato(Kyoto University Hospital), Hiroki Sakamoto(Kokura Memorial Hospital), Kyohei Yamaji(Kokura Memorial Hospital)
The American Journal of Cardiology
November 28, 2021
10.1016/j.amjcard.2021.10.032
Cited by 33

Related Papers

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|848
Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial
|The Lancet Diabetes & Endocrinology|2019|673
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Three-Year Follow-up after Implantation of Metallic Coronary-Artery Stents
|New England Journal of Medicine|1996|507